Payment overview · 2025
General Payments
$254.71
5 reported records · 2 companies
Healthcare provider profile · identity verified
Alvin Torres, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · CAYEY, PR · NPI 1952364408
Verified facts
What the public records show
CMS Open Payments records show Alvin Torres, M.D received $254.71 in general payments during 2025 across 5 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $134.76 | 52.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.95 | 47.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.71 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $134.76 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 158 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 176 |
| Famotidine | Famotidine | 786 | 169 |
| Synthroid | Levothyroxine Sodium | 743 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 467 | 97 |
| Losartan Potassium | Losartan Potassium | 455 | 98 |
| Simvastatin | Simvastatin | 386 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 87 |
| Gabapentin | Gabapentin | 338 | 81 |
| Metformin Hcl | Metformin Hcl | 321 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 319 | 78 |
| Irbesartan | Irbesartan | 295 | 65 |
| Farxiga | Dapagliflozin Propanediol | 287 | 50 |
| Lisinopril | Lisinopril | 273 | 55 |
| Glimepiride | Glimepiride | 237 | 49 |
| Clonazepam | Clonazepam | 199 | 48 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 198 | 35 |
| Carvedilol | Carvedilol | 194 | 46 |
| Alendronate Sodium | Alendronate Sodium | 173 | 47 |
| Doxazosin Mesylate | Doxazosin Mesylate | 168 | 35 |
| Allopurinol | Allopurinol | 165 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 49 |
| Jardiance | Empagliflozin | 158 | 27 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 158 | 19 |
| Montelukast Sodium | Montelukast Sodium | 157 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 57 |
| Trazodone Hcl | Trazodone Hcl | 155 | 31 |
| Temazepam | Temazepam | 147 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 125 | 40 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 122 | 52 |
| Memantine Hcl | Memantine Hcl | 121 | 33 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 120 | 17 |
| Sertraline Hcl | Sertraline Hcl | 117 | 32 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 113 | 27 |
| Humulin N | Insulin Nph Human Isophane | 113 | 18 |
| Xarelto | Rivaroxaban | 108 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 25 |
| Eliquis | Apixaban | 102 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 23 |
| Lorazepam | Lorazepam | 95 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 21 |
| Buspirone Hcl | Buspirone Hcl | 88 | 30 |
| Furosemide | Furosemide | 84 | 25 |
| Candesartan Cilexetil | Candesartan Cilexetil | 80 | 22 |
| Nifedipine Er | Nifedipine | 78 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 75 | 25 |
| Ramipril | Ramipril | 74 | 16 |
| Spironolactone | Spironolactone | 73 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 18 |
| Cilostazol | Cilostazol | 68 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 67 | 20 |
| Diclofenac Potassium | Diclofenac Potassium | 65 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 13 |
| Brilinta | Ticagrelor | 61 | 14 |
| Finasteride | Finasteride | 61 | 16 |
| Ezetimibe | Ezetimibe | 60 | 13 |
| Rivastigmine | Rivastigmine | 58 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 54 | suppressed |
| Humalog | Insulin Lispro | 53 | suppressed |
| Meloxicam | Meloxicam | 49 | 25 |
| Memantine Hcl Er | Memantine Hcl | 48 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 12 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 40 |
| Meclizine Hcl | Meclizine Hcl | 44 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Methotrexate | Methotrexate Sodium | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Prednisone | Prednisone | 41 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 38 | suppressed |
| Kerendia | Finerenone | 38 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 38 | 34 |
| Nisoldipine | Nisoldipine | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | 17 |
| Galantamine Er | Galantamine Hbr | 27 | 11 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 22 |
| Pentoxifylline | Pentoxifylline | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 24 | 11 |
| Tegretol Xr | Carbamazepine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Fenofibrate | Fenofibrate | 21 | 11 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valsartan | Valsartan | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | 11 |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Estazolam | Estazolam | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.71 · 5 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error